Global Consumer Healthcare Market 2016-2020

2016-02-24
Price :
Published : Feb-2016
No. of Pages : 105

The characteristics of consumer health products vary widely, with the two most important elements being the consumer needs they address and the strength of the claims made. The market for consumer-focused healthcare products is increasingly occupying the space between consumer needs and growing prevalence of lifestyle diseases. As consumer health companies develop a combination of consumer goods and pharmaceuticals, they have the ability to engage consumers by proving the clinical effectiveness of their products. These companies recognize unmet consumer needs and develop inventive ways to establish their presence in the marketplace.

Allergy care, dietary supplements, feminine care, pain relief, respiratory, and oral health are among the popular consumer health product categories. Some well-known products in the market are Voltaren and Panadol by GlaxoSmithKline; Lactacyd and Dermacyd by Sanofi; and Nexium, Advil, and Caltrate by Pfizer.

The analysts forecast global consumer healthcare market to grow at a CAGR of 9.26% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global consumer healthcare market for the period 2016-2020. To calculate the market size, the report considers revenue generated from the sales of OTC pharmaceuticals and dietary supplements.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Consumer Healthcare Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors

  • Bayer HealthCare
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi

Other prominent vendors

  • Abbott Laboratories
  • American Health
  • Amway
  • Arena Pharmaceuticals
  • BASF
  • BioGaia
  • Bukwang Pharmaceutica
  • Chr. Hansen
  • Danone
  • DSM
  • Eisai
  • EMS
  • Euradite Consumer Health and Life Care
  • Friggs
  • Genomma Lab Internacional
  • Glanbia
  • Herbalife
  • The Himalaya Drug Company
  • Kellogg
  • McNeil Consumer Healthcare
  • Mead Johnson Nutrition
  • Merck
  • Mitsubishi Tanabe Pharma
  • NestlĂ©
  • Novartis
  • Nutrition & SantĂ©
  • Omega Pharma
  • Procter & Gamble
  • Reckitt Benckiser
  • SAVA Global
  • Sigma Pharmaceuticals
  • Sun Pharma
  • Taisho Pharmaceuticals
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals
  • Unifarma Global Consumer Healthcare
  • Vida Laboratories
  • Yakult Danone India

Market driver

  • Awareness about lifestyle diseases
  • For a full, detailed list, view our report

Market challenge

  • Intense competition
  • For a full, detailed list, view our report

Market trend

  • Accelerated use of online resources
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the Key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Alzheimer’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026 Summary Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide. To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Sta......
$3995

EpiCast Report: Epilepsy – Epidemiology Forecast to 2026

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026 Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014). In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% pe......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report p......
$1000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Argentina

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina Summary Pharmaceutical market increased from over US$3 Billion in 2009 to around US$6.5 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of nearly 10%. It is expected to cross US$10 Billion in 2021 at a CAGR of about 10%. In 2009, the medical device market was valued at just over US$1 Billion. It grew at a CAGR of 4% between 2009 and 2016 and reached around US$1.3 Billion. It is expected to grow at a CAGR of about 5%, from around US$1.4 Billion in 2017 to over US$1.7 Billion in 2021. Argentina is the third-largest pharmaceutical market in Latin America after Brazil and Mexico. With a relatively low-cost base and high-quality professionals in the biotechnology sector, Argentina is home to over 130 ......
$1995

EpiCast Report: Melanoma – Epidemiology Forecast to 2026

EpiCast Report: Melanoma - Epidemiology Forecast to 2026 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013). In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagn......
$3995

EpiCast Report: Crohn’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026 Summary Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel. Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 a......
$3995

Hyperammonemia Global Clinical Trials Review, H2, 2017

Hyperammonemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperammonemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperammonemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperammonemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Hyperparathyroidism Global Clinical Trials Review, H2, 2017

Hyperparathyroidism Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperparathyroidism Global Clinical Trials Review, H2, 2017" provides an overview of Hyperparathyroidism clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperparathyroidism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Hyperandrogenism Global Clinical Trials Review, H2, 2017

Hyperandrogenism Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperandrogenism Global Clinical Trials Review, H2, 2017" provides an overview of Hyperandrogenism clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperandrogenism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Hyperphenylalaninemia Global Clinical Trials Review, H2, 2017

Hyperphenylalaninemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperphenylalaninemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperphenylalaninemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphenylalaninemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500